CDER chief says ‘standards have not changed,’ explaining increase in CRLs for biologics

The FDA initially rejected nearly half of all biologics applications received last year, many for quality-related CMC issues that need to be improved upon, according …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The need to know biotech news stories today

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hi! It’s Meghana. Today,

February 13, 2024

Orion sees highest filings and grants during May in Q2 2024

Orion has been focused on protecting inventions in United States(US) with eight publications in Q2 2024 The United States(US) Patent Office dominates the patent filings

July 21, 2024

Actimed plans trials to treat muscle wasting syndrome in cancer patients

Actimed plans to start two Phase IIb/III trials of its lead candidate in H1 2024. Credit: Shutterstock / Casa nayafana. UK-based Actimed Therapeutics is planning

July 13, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.